Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pregabalin→

Pregabalin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
148553-50-8
Molecular formula
C8H17NO2
Molecular weight
159.23 g/mol
Drug class
Gabapentinoidligand of the alpha-2-delta subunit of voltage-gated calcium channels
Mechanism of action
Binds with high affinity to the alpha-2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system, reducing calcium influx and release of excitatory neurotransmitters. It is not a direct GABA receptor agonist.
Indications / reported uses
  • Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury in adults, according to product label
  • Adjunctive treatment of partial-onset seizures in eligible patients
  • Fibromyalgia in adults under the US product indication; use for other pain syndromes may be off-label and jurisdiction-specific

Sources: US DailyMed — Pregabalin · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Gabapentinoid; ligand of the alpha-2-delta subunit of voltage-gated calcium channels

Mechanism of action

Binds with high affinity to the alpha-2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system, reducing calcium influx and release of excitatory neurotransmitters. It is not a direct GABA receptor agonist.

General use cases

  • Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury in adults, according to product label
  • Adjunctive treatment of partial-onset seizures in eligible patients
  • Fibromyalgia in adults under the US product indication; use for other pain syndromes may be off-label and jurisdiction-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Pregabalin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pregabalin Permitted Daily Exposure (PDE) report (the Pregabalin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pregabalin Occupational Exposure Limit (OEL) report (the Pregabalin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.